Shogo Zuo1, Masayuki Sho2, Toshio Sawai1, Hiromichi Kanehiro1, Kosaku Maeda3, Makiko Yoshida4, Ryo Tsukada5, Motonari Nomura5, Hiroomi Okuyama5. 1. Department of Surgery, Nara Medical University, Shijocho 840, Kashihara, Nara, 634-8522, Japan. 2. Department of Surgery, Nara Medical University, Shijocho 840, Kashihara, Nara, 634-8522, Japan. m-sho@naramed-u.ac.jp. 3. Department of Pediatric Surgery, Kobe Children's Hospital, Hyogo, Japan. 4. Department of Pathology, Kobe Children's Hospital, Hyogo, Japan. 5. Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Abstract
PURPOSE: The programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway has garnered much attention for its roles in clinical oncology. The aim of this study was to examine the clinical impact of the PD-L1 expression and tumor-infiltrating lymphocytes (TILs) on neuroblastoma. METHODS: We evaluated the PD-L1 expression and TIL status in 31 patients with neuroblastoma who underwent a biopsy or resection by an immunohistochemical analysis. Furthermore, we performed the serial analysis of the PD-L1 status before and after chemotherapy in 15 patients. RESULTS: Among the 31 cases, 11 (35%) showed a positive PD-L1 expression. The survival analysis showed a trend toward an association between PD-L1 positivity and a decreased overall survival. PD-L1 positivity tended to be associated with higher levels of tumor markers. In the serial analysis of the PD-L1 status, positivity was noted in 8 of 15 patients before chemotherapy and 6 after chemotherapy. Notably, all four patients with a positive PD-L1 status both before and after chemotherapy had recurrence, and 3 of them died during the follow-up period. CONCLUSION: Our findings suggest that the PD-L1 tumor expression might be a good biomarker for the treatment of neuroblastoma patients, especially for advanced neuroblastoma.
PURPOSE: The programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway has garnered much attention for its roles in clinical oncology. The aim of this study was to examine the clinical impact of the PD-L1 expression and tumor-infiltrating lymphocytes (TILs) on neuroblastoma. METHODS: We evaluated the PD-L1 expression and TIL status in 31 patients with neuroblastoma who underwent a biopsy or resection by an immunohistochemical analysis. Furthermore, we performed the serial analysis of the PD-L1 status before and after chemotherapy in 15 patients. RESULTS: Among the 31 cases, 11 (35%) showed a positive PD-L1 expression. The survival analysis showed a trend toward an association between PD-L1 positivity and a decreased overall survival. PD-L1 positivity tended to be associated with higher levels of tumor markers. In the serial analysis of the PD-L1 status, positivity was noted in 8 of 15 patients before chemotherapy and 6 after chemotherapy. Notably, all four patients with a positive PD-L1 status both before and after chemotherapy had recurrence, and 3 of them died during the follow-up period. CONCLUSION: Our findings suggest that the PD-L1tumor expression might be a good biomarker for the treatment of neuroblastomapatients, especially for advanced neuroblastoma.
Authors: Anup S Pathania; Philip Prathipati; Omalla A Olwenyi; Srinivas Chava; Oghenetejiri V Smith; Subash C Gupta; Nagendra K Chaturvedi; Siddappa N Byrareddy; Don W Coulter; Kishore B Challagundla Journal: Mol Ther Oncolytics Date: 2022-03-31 Impact factor: 6.311
Authors: Nicholas J Skertich; Fei Chu; Imad A M Tarhoni; Stephen Szajek; Jeffrey A Borgia; Mary Beth Madonna Journal: Cancers (Basel) Date: 2022-01-31 Impact factor: 6.639